McMillen TS, Heinecke JW, LeBoeuf RCExpression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation2005;111:2798.
3.
Elsayed E., Becker RCThe impact of heparin compounds on cellular inflammatory responses: A construct for future investigation and pharmaceutical development. J Thromb Thrombolysis2003;15:11.
4.
Baldus S., Eiserich JP, Mani A., et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest2001;108:1759.
5.
Daphna EM, Michaela S., Eynat P., et al. Association of myeloperoxidase with heparin: Oxidative inactivation of proteins on the surface of endothelial cells by the bound enzyme. Mol Cell Biochem1998;183:55.
6.
Bos JC, Grooteman Mpc, van Houte AJ, et al. Low polymorphonuclear cell degranulation during citrate anticoagulation: A comparison between citrate and heparin dialysis. Nephrol Dial Transplant1997;12:1387.
7.
Inose K., Ono K., Tsuchida A., et al. Active inhibitory effect of nafamostat mesylate against the elevation of plasma myeloperoxidase during hemodialysis. Nephron1997;75: 420.
8.
Baldus S., Rudolph V., Roiss M., et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation2006; 113:1871.
9.
Borawski J.Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Am J Kidney Dis2006;47:37.
10.
Borawski J. , Naumnik B., Rydzewska-Rosolowska A., Mysliwiec M.Myeloperoxidase up-regulation during haemodialysis: is heparin the missing link?Nephrol Dial Transplant2006;21:128.